Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial.

ABSTRACT:

Background

Kidney pain is a common complication in patients with autosomal dominant polycystic kidney disease (ADPKD), and data from the TEMPO 3:4 trial suggested that tolvaptan, a vasopressin V2 receptor antagonist, may have a positive effect on kidney pain in this patient group. Because pain is difficult to measure, the incidence of kidney pain leading to objective medical interventions was used in the present study to assess pain.

Study design

Secondary analysis from a randomized controlled trial.

Setting & participants

Patients with ADPKD with preserved kidney function.

Intervention

Tolvaptan or placebo.

Outcomes

Kidney pain events defined by objective medical interventions.

Measurements

Kidney pain events were recorded and independently adjud

SUBMITTER: Casteleijn NF 

PROVIDER: S-EPMC5497700 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature